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Abstract
Background: MUC16 is a cell surface mucin expressed at high levels by epithelial ovarian tumors. Following 
proteolytic cleavage, cell surface MUC16 (csMUC16) is shed in the extracellular milieu and is detected in the serum of 
cancer patients as the tumor marker CA125. csMUC16 acts as an adhesion molecule and facilitates peritoneal 
metastasis of ovarian tumors. Both sMUC16 and csMUC16 also protect cancer cells from cytotoxic responses of natural 
killer (NK) cells. In a previous study we demonstrated that sMUC16 binds to specific subset of NK cells. Here, we identify 
the csMUC16/sMUC16 binding partner expressed on immune cells.
Results: Analysis of immune cells from the peripheral blood and peritoneal fluid of ovarian cancer patients indicates 
that in addition to NK cells, sMUC16 also binds to B cells and monocytes isolated from the peripheral blood and 
peritoneal fluid. I-type lectin, Siglec-9, is identified as the sMUC16 receptor on these immune cells. Siglec-9 is expressed 
on approximately 30-40% of CD16pos/CD56dim NK cells, 20-30% of B cells and >95% of monocytes. sMUC16 binds to the 
majority of the Siglec-9pos NK cells, B cells and monocytes. sMUC16 is released from the immune cells following 
neuraminidase treatment. Siglec-9 transfected Jurkat cells and monocytes isolated from healthy donors bind to 
ovarian tumor cells via Siglec-9-csMUC16 interaction.
Conclusions: Recent studies indicate that csMUC16 can act as an anti-adhesive agent that blocks tumor-immune cell 
interactions. Our results demonstrate that similar to other mucins, csMUC16 can also facilitate cell adhesion by 
interacting with a suitable binding partner such as mesothelin or Siglec-9. Siglec-9 is an inhibitory receptor that 
attenuates T cell and NK cell function. sMUC16/csMUC16-Siglec-9 binding likely mediates inhibition of anti-tumor 
immune responses.
Introduction
MUC16 is a membrane spanning mucin that is expressed
on ovarian, endometrial, tracheal, and ocular surface epi-
thelial cells [1-4]. This mucin is initially expressed on the
surface (cell surface MUC16, csMUC16) and then shed
(shed MUC16, sMUC16) in the extracellular milieu fol-
lowing proteolytic cleavage [5-7]. csMUC16 carries a
~12,000 amino acid N-terminal region, a Variable Num-
ber of Tandem Repeat (VNTR) domain composed of 60
tandem repeats of 156 amino acids, and a 256 amino acid
cytoplasmic tail [7-9]. The mucin is heavily glycosylated
with both O- and N-linked oligosaccharides [10]. Because
of all of these structural features, the average molecular
weight of csMUC16 and sMUC16 is between 3-5 million
Da [7,9,10].
csMUC16 is overexpressed by human epithelial ovarian
tumor cells [11,12]. sMUC16 is released by ovarian
tumors and can be detected in the peritoneal fluid and
peripheral blood of cancer patients. A repeating peptide
epitope present in the VNTR domain of csMUC16 and
sMUC16 has been previously identified as the tumor
marker CA125. Elevations, from an individualized nadir
serum concentration of CA125, are routinely determined
in order to monitor progression of epithelial ovarian can-
cer in patients undergoing treatment for this disease
[13,14].
In addition to serving as a cancer biomarker, MUC16 is
also important in promoting the metastasis and growth
of ovarian tumors. csMUC16 facilitates tumor cell aggre-
gation and their subsequent binding to the peritoneal
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surfaces by serving as a ligand of mesothelin, a glycopro-
tein expressed on mesothelial cells [15-17]. Both
csMUC16 and sMUC16 protect ovarian tumor cells from
immune attack and thereby promote tumor growth.
sMUC16 is an inhibitor of the cytolytic anti-tumor
responses of natural killer (NK) cells [18]. On the other
hand, csMUC16 acts as an anti-adhesive molecule and
prevents the formation of the immunological synapse
between ovarian cancer cells and NK cells [19]. Addi-
tional studies are required to carefully delineate the
immunoprotective role of sMUC16 and csMUC16 and
their contribution to the progression of ovarian tumori-
genesis.
Phenotypic analysis of NK cells isolated from the
peripheral blood and peritoneal fluid of ovarian cancer
demonstrated that sMUC16 derived from the tumors
binds strongly to the surface of a select subset of
CD16pos/CD56dim NK cells [20]. RT-PCR of peripheral
blood mononuclear cells (PBMC) from ovarian cancer
patients and other in vitro experiments, reported in our
previous study, showed that immune cells do not express
MUC16 [20]. sMUC16 was detected on the immune cell
surface using the murine monoclonal antibodies VK8,
and OC125 [20]. Both VK8 and OC125 are highly specific
anti-MUC16 antibodies. VK-8 was used in experiments
that ultimately led to the cloning of MUC16 [6,21] and
the OC125 antibody was used as a reagent to establish
the clinical-grade CA125 assay to measure the concentra-
tion of this marker in the sera of cancer patients [22,23].
A third antibody, 618F, developed by our group [24], also
binds specifically to subsets of CD16pos/CD56dim NK cells
isolated from ovarian cancer patients but not to those
obtained from healthy donors (Patankar et al unpub-
lished data). Lack of endogenous MUC16 expression and
the binding of highly specific anti-MUC16 antibodies to
only fixed subsets of patient derived immune cells sug-
gested the presence of a MUC16 receptor on immune
cells. The current study was therefore undertaken to
identify the binding partner for MUC16 on immune cells.
Here, we report that sMUC16 selectively binds not only
to a subset of CD16pos/CD56dim NK cells but also is pres-
ent on the surface of approximately 20% of the CD19pos B
cells and >90% of all CD14pos  monocytes. Additional
experiments demonstrate that both sMUC16 and
csMUC16 bind to the immune cell surface via the I-type
lectin Siglec-9. csMUC16-Siglec-9 binding mediates
adhesion of immune cells with ovarian tumor cells. Iden-
tification of Siglec-9 as the sMUC16/csMUC16 binding
partner provides an opportunity to identify the molecular
mechanisms that lead to suppression of immune
responses by this mucin. Apart from its importance in
understanding the biological role of MUC16, the data
also suggests that sMUC16 binding to immune cells may
serve as a novel strategy for the detection and monitoring
of ovarian cancer.
Results
Potential sMUC16 receptors on CD16pos/CD56dim NK cell 
surface
Human NK cells are classified into two major pheno-
types, CD16pos/CD56dim  and CD16neg/CD56bright. The
CD16pos/CD56dim NK cells are highly cytotoxic NK cells
whereas the CD16neg/CD56bright NK cells are not efficient
in lysing tumor targets [25,26]. Because sMUC16 binds
only to subsets of CD16pos/CD56dim NK cells and also
inhibits their cytolytic activity, we postulated that
sMUC16 is likely a ligand of an inhibitory receptor on NK
cells. Since sMUC16 is heavily glycosylated, we specifi-
cally considered carbohydrate binding receptors of NK
cells as potential binding partners.
The lectin galectin-1 has been reported as a MUC16
receptor on NK cells [27,28]. However, galectin-1 is pri-
marily expressed by CD16dim/CD56bright NK cells (Addi-
tional file 1) while MUC16 is bound by CD16pos/CD56dim
NK cells. Therefore, galectin-1 was considered unlikely to
be involved in mediating binding of sMUC16 to CD16pos/
CD56dim NK cells. Another binding partner for sMUC16
is mesothelin [15]. This glycoprotein is however not
expressed on NK cells based on microarray analysis [29].
To test if sMUC16 was binding to immune cells via its
oligosaccharides, we digested the peripheral blood mono-
nuclear cells (PBMC) from ovarian cancer patients with
neuraminidase from Clostridium perfringens. After a lim-
ited (15 min) digestion with neuraminidase, the PBMC
were monitored by flow cytometry for the amount of
sMUC16 still bound to the cell surface. Neuraminidase
treatment resulted in a loss of sMUC16 binding on
approximately 50% of the PBMCs as compared to match-
ing controls not treated with neuraminidase (Figure 1).
NK cells are reported to express two members of the
sialic acid binding Siglec family, Siglec-7 and Siglec-9
[30,31]. Siglec-9 recognizes α2-3-linked sialic acid where
as Siglec-7 preferentially binds to glycans terminated with
α2-8-linked sialic acid residues [32,33]. Glycomic analysis
has revealed extensive expression of α2-3-linked sialic
acid residues on MUC16 [10]. Therefore, we focused our
attention on Siglec-9 as a potential candidate immune cell
receptor for this mucin.
sMUC16 predominantly binds to Siglec-9pos/CD16pos/
CD56dim NK cells
Analysis of NK cells from the peripheral blood (PB) of
four healthy donors indicated that Siglec-9 was detectable
only on approximately 15-40% of the CD16pos/CD56dim
cells (Figure 2A). The CD16neg/CD56bright NK cells were
either negative or presented very low levels of Siglec-9Belisle et al. Molecular Cancer 2010, 9:118
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(Figure 2A). A similar expression pattern for Siglec-9 was
also observed on NK cells from PB and peritoneal fluid
(PF) of epithelial ovarian cancer patients (Figure 2A).
As mentioned previously, sMUC16 is detected only on
30-40% of the CD16pos/CD56dim NK cells isolated from
the PB and PF of ovarian cancer patients, the same subset
of NK cells that also are likely to express Siglec-9. W e
therefore performed multi-color flow cytometry experi-
ments to determine if sMUC16 was selectively binding to
the Siglec-9pos/CD16pos/CD56dim NK cell subset. While
Siglec-9 was detected on the CD16pos/CD56dim NK cells
isolated from the PB of healthy donors, the level of
sMUC16 on these cells was either undetectable or very
low (Figure 2B, C). To the contrary, between 74-82% of
the Siglec-9pos/CD16pos/CD56dim NK cells isolated from
the PB and PF of five ovarian cancer patients were also
positive (double positive) for sMUC16 (Figure 2C). The
differences between the percentage of patient PB- and
PF-derived CD16pos/CD56dim NK cells that were positive
for Siglec-9 and sMUC16 were statistically not significant
(Figure 2C).
Siglec-9 expression on B cells and monocytes
The PB and PF derived mononuclear cells (PBMC and
PFMC) contain B cells, T cells, and monocytes in addi-
tion to the NK cells. Only a very minor subset (less than
2%) of the PBMC and PFMC derived CD3pos T cells
expressed Siglec-9 (data not shown). Furthermore, only
low levels of Siglec-9 was observed on these T cells. We
generally did not observe sMUC16 binding to the small
percentage of these Siglec-9pos T cells. However, because
of the low number of events of Siglec-9pos T cells and low
levels of expression of this receptor, we were unable to
obtain statistically relevant information on sMUC16
binding to T cells of all of the healthy donors and ovarian
c a n c e r  p a t i e n t s  r e c r u i t e d  i n  t h i s  s t u d y .  H e n c e ,  T  c e l l s
were not further analyzed for sMUC16 binding and
Siglec-9 expression.
Approximately 20% of CD19pos B cells and greater than
90% of the CD33pos monocytes were Siglec-9pos (Figure 3).
The expression level of Siglec-9 on B cells and NK cells
was comparable. However, the entire population of the
CD33pos monocytes expressed several fold higher levels
of Siglec-9 as compared to the B cells and NK cells (Figure
3).
sMUC16 is present on Siglec-9pos B cells and monocytes
If sMUC16 was binding to NK cells via Siglec-9, this
mucin should also be present on the Siglec-9pos B cells
and monocytes. This was indeed the case since 65-70% of
the total sMUC16pos B cells were also Siglec-9pos (Figure
4A). In the case of monocytes the correlation between
sMUC16 binding and Siglec-9 expression was even more
striking. Greater than 95% of the sMUC16pos monocytes
were Siglec-9pos and vice versa (Figure 4B and 4C). Over-
all, the mean fluorescent intensity for sMUC16 binding to
the B cells, NK cells, and monocytes matched the expres-
sion levels of Siglec-9 on these immune cell types (data
not shown).
sMUC16 binds to Siglec-9
In Western blot analysis sMUC16 purified from OVCAR-
3 cells was detected by the Siglec-9-human Fc chimera
(Figure 5A). Fetuin, an α2,3-sialic acid expressing glyco-
protein, blocked the binding of Siglec-9 human Fc chi-
mera to sMUC16 (Figure 5B). Asialofetuin under
identical conditions did not abrogate the binding of
Siglec-9-human Fc to sMUC16 (Figure 5B).
To further demonstrate that Siglec-9-human Fc was
recognizing the sialic acids of sMUC16 the mucin was
digested with neuraminidase. Efficient desialylation of
sMUC16 was demonstrated by the increased migration of
asialo-sMUC16 detected by Western blot analysis using
the anti-MUC16 antibody VK-8 (Figure 5C). Enzymati-
cally desialylated sMUC16 was not recognized by the
Siglec-9-human Fc chimera (Figure 5C).
Specificity of sMUC16 binding to Siglec-9 was deter-
mined using Jurkat cells transfected with cDNA coding
for this I-type lectin [34]. The Siglec-9 expressing Jurkat
cells were incubated with either sMUC16 (50,000 U of
Figure 1 sMUC16 binding to immune cells is reduced following 
neuraminidase treatment. PBMC from each of six ovarian cancer pa-
tients were digested with neuraminidase from Clostridium perfringens 
in phosphate buffered saline (PBS). Matching control PBMC from each 
of the six patients were treated with heat inactivated neuraminidase 
(Clostridium perfringens). sMUC16 binding to the control and enzymat-
ically digested cells was measured by flow cytometry using the anti-
MUC16 antibody, VK-8. Each bar is the mean measurement for all six 
donors. Data was analyzed using the Wilcoxon signed rank test.
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CA125/ml) purified from the conditioned media of
OVCAR-3 cells or with peritoneal fluid from two ovarian
cancer patients. After culture for 24 h (Figure 6A),
sMUC16 was detected on Siglec-9 expressing Jurkat cells.
Matched Jurkat cells that expressed Siglec-7 instead of
Siglec-9 did not show any binding of sMUC16 under
identical conditions (Figure 6A).
To further demonstrate that sMUC16 was binding to
Siglec-9 expressing Jurkat cells via its sialic acid residues,
purified mucin was desialylated with neuraminidase from
Clostridium perfringens. The limited availability of puri-
fied sMUC16 compelled us to conduct neuraminidase
treatment in cell culture compatible buffer (pH 7.4). The
neuraminidase has an optimum pH of 5 [35]. Hence,
Figure 2 sMUC16 predominantly binds to Siglec-9pos/CD16pos/CD56dim NK cells. Peripheral blood mononuclear cells (PBMC) from healthy do-
nors (HD) and patients (PT) and peritoneal fluid mononuclear cells (PFMC) of PT were labeled with VK8 followed by a fluorophore conjugated second-
ary reporter antibody. The cells were subsequently labeled with fluorescently tagged anti-CD3, -CD16, -CD56, -Siglec-9, and -NKp46 antibodies as 
described earlier [20]. NK cells identified as CD3neg/NKp46pos cells were classified into CD16pos/CD56dim and CD16neg/CD56bright cells by flow cytometry. 
A, Siglec-9 expression on the two NK cell subpopulations, CD16pos/CD56dim and CD16neg/CD56bright, was analyzed. Each bar represents a mean and 
standard deviation of three independent experiments. B and C, sMUC16 binding and Siglec-9 expression on CD16pos/CD56dim NK isolated from PBMC 
of healthy donors and PBMC and PFMC of cancer patients was determined. B, shows dot plots of representative healthy donor (HD) peripheral blood 
NK and patient (PT) NK cells from peripheral blood (PB) and peritoneal fluid (PF). Majority of events in the lower left quadrant are located on the axes 
and therefore not visible in the dot plots. C, Each value is mean of PBMC from 6 healthy donor and PBMC and PFMC from five cancer patients showing 
percent of the cells positive for Siglec-9 and sMUC16 and those double positive for both Siglec-9 and sMUC16 are shown.
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digestion with this neuraminidase at pH 7.4 yielded only
partial desialylation of sMUC16- as confirmed by western
blotting experiments with VK-8 and biotinylated Mackia
amurensis agglutinin (data not shown). The partially desi-
alylated sMUC16 exhibited a 20-50% reduction in the
binding to Siglec-9 expressing Jurkat cells (Figure 6B).
Siglec-9 promotes immune cell-tumor cell adhesion via 
csMUC16
MUC1 binding to Siglec-4a (myelin associated glycopro-
tein) contributes to perineural adhesion of pancreatic
cancer cells [36]. We therefore investigated if Siglec-9
could also promote immune cell-tumor cell adhesion via
csMUC16 expressed on ovarian cancer cells.
To demonstrate the ability of Siglec-9 to act as a cell
binding receptor, we utilized MUC16 knock down
OVCAR-3 subline csMUC16negOVC and MUC16
expressing OVCAR-3 subline MUC16posOVC [16,37].
The csMUC16negOVC cells express an endoplasmic retic-
ulum localized scFv fragment of the VK8 antibody that
prevents expression of csMUC16 and sMUC16. The
OVCAR-3 subline csMUC16posOVC expresses endoplas-
mic reticulum localized scFv fragment of an irrelevant
mouse antibody that does not interfere with csMUC16
and sMUC16 expression.
Using two separate cell adhesion assays it was deter-
mined that Siglec-9 expressing Jurkat cells formed
approximately 1.5-2-fold more cell conjugates with
csMUC16posOVC cells as compared to csMUC16negOVC
cells. Siglec-7 expressing Jurkat cells, most likely via
Siglec-7-independent mechanisms, did indeed form con-
jugates with both csMUC16negOVC and
csMUC16posOVC cells (Figure 7A, B). However, signifi-
cantly more conjugate formation was observed between
Siglec-9 expressing Jurkat cells and csMUC16posOVC
cells than between Siglec-7 expressing Jurkat and
csMUC16posOVC cells (Figure 7A, B).
Cell binding assays were also performed with mono-
cytes isolated from the PB of healthy donors. Similar to
results obtained with the Siglec-9 and Siglec-7 expressing
Jurkat cells, basal level of binding of monocytes was
observed with the csMUC16neg-OVC. However, in five
independent experiments conducted with monocytes
isolated from three healthy donors, increased binding of
the monocytes to the csMUC16pos-OVC as compared to
the csMUC16neg-OVC was consistently observed. The
increased binding of monocytes to the csMUC16pos-OVC
was significantly inhibited by an anti-Siglec-9 blocking
antibody (Figure 8) [38].
Discussion
Mucins are bulky, heavily glycosylated molecules that are
known to function in diverse biological scenarios [39,40].
One of the intriguing properties of mucins is their ability
to act as both adhesive as well as anti-adhesive molecules.
The bulky nature of the mucins coupled with the pres-
ence of negatively charged oligosaccharides contributes
to their anti-adhesive properties. On the other hand, spe-
cific oligosaccharide and peptide sequences of mucins
may serve as ligands for cell adhesion receptors such as
the selectins and integrins thereby allowing mucins to act
as pro-adhesion molecules.
Similar to other mucins, MUC16 also exhibits both
anti- and pro-adhesive properties. By serving as a ligand
of mesothelin, MUC16 mediates binding between ovar-
ian cancer cells and the mesothelium [15,16]. The anti-
adhesive property of MUC16 has been clearly demon-
strated in the human endometrial tissues [3]. Our recent
work [19] shows that the anti-adhesive property of
MUC16 allows the tumor cells to circumvent immune
synapse formation with cytotoxic NK cells.
In the current study, we have now identified a new
mechanism by which csMUC16 may increase the con-
tacts between ovarian cancer cells and immune cells.
Figure 3 Expression of Siglec-9 on NK cells, B cells and monocytes. PBMC from healthy donors (HD) and PBMC and PFMC from patients (PT) were 
labeled with fluorophore conjugated anti-CD3, -CD19, -CD16, -CD33, -CD45, -CD56, and -Siglec-9 antibodies. Cells were analyzed by flow cytometry. 
Live and single events were gated and expression of Siglec-9 on CD16pos/CD56dim (NK) cells, CD19pos B cells, and CD33pos monocytes was determined. 
Data shown for HD #29 and PT#36 is representative of that obtained for four healthy donors and five ovarian cancer patients, respectively.
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Figure 4 sMUC16 predominantly binds to Siglec-9pos B cells and monocytes. B cells (CD19pos) and monocytes (CD33pos) present in the PBMC of 
healthy donors (HD) and PBMC and PFMC of ovarian cancer patients (PT) were identified by flow cytometry. A, Siglec-9 expression and sMUC16 bind-
ing on B cells was determined and double positive events were gated. Data shown is mean of percent positive events for six HD and five PT PBMC 
samples. B, High level of expression of Siglec-9 and a correspondingly high level of sMUC16 binding was observed on monocytes. Data shown is for 
HD #29 and PT #36 and is representative of the cumulative data, C, obtained for six HD and five PT.
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Here, we have identified Siglec-9 as the immune cell
receptor for sMUC16 and csMUC16. The binding of
csMUC16 to Siglec-9 allows immune cells to form direct
contact with the ovarian cancer cells. Thus, while on the
one hand, csMUC16 blocks immune synapse formation,
the results of the current study indicate that the mucin
may allow increased immune cell binding to ovarian can-
cer cells. These seemingly contradictory observations
can, however, be reconciled.
Siglec-9 is an inhibitory receptor that signals via its
proximal Immunoreceptor Tyrosine-based Inhibition
Motif (ITIM). Ligand binding results in the phosphoryla-
Figure 5 Siglec-9 binds to sialylated glycans of sMUC16. A, Fetuin (lane 1) or sMUC16 (300 U of CA125, lane 2; 200 U of CA125, lane 3; and 100 U 
of CA125, lane 4) were separated by SDS-PAGE, transferred to a PVDF membrane and overlaid with Siglec-9-human Fc chimera (2.5 nM). Binding of 
Siglec-9-human-Fc was detected using horseradish-peroxidase-labeled mouse anti-human-Fc secondary antibody. B, sMUC16 (250 U of CA125/lane) 
purified from the spent media of OVCAR-3 cells was loaded in duplicate on both blots. Siglec-9-human-Fc chimera was overlaid on the membrane in 
the presence of 7.5 nM asialofetuin (left panel) or fetuin (right panel). C, sMUC16 was desialylated with neuraminidase from Clostridium perfringens. 
Binding of neuraminidase treated and untreated sMUC16 samples (250 U of CA125/lane) to VK-8 (left panel) or Siglec-9-human-Fc (right panel) was 
detected by Western blotting. Red arrows in all panels indicate interface between the stacking and separating gels. sMUC16 is typically retained in the 
stacking gel under the electrophoresis conditions used to develop these western blots. Migration of the 200 kDa (A-C) and 60 kDa (A) molecular 
weight markers is shown.
2 34 1
200 kDa-
60 kDa-
A
B
+ Asialofetuin + Fetuin 
-200 kDa-
Probed with VK8+ 20 Probed with Siglec-9-Fc+20
-200 kDa-
CBelisle et al. Molecular Cancer 2010, 9:118
http://www.molecular-cancer.com/content/9/1/118
Page 8 of 14
tion of tyrosine residues in the ITIM and the recruitment
and activation of the phosphatases SHP-1 and SHP-2
[34,41]. Because of the activation of these two phos-
phatases, binding of Siglec-9 to its ligands results in
potent inhibition of NK cell and T cell anti-tumor func-
tions [34,41]. Furthermore, engagement of Siglec-9 on
monocytic cells results in the secretion of the immuno-
suppressive cytokine IL-10 [42].
In over 20 ovarian cancer patient samples analyzed to
date we have invariably found sMUC16 attached to the
surface of specific immune cell subsets [20]. Data pre-
sented in the current study demonstrates that sMUC16
predominantly binds to NK cells, B cells and monocytes
via Siglec-9. These observations suggest that sMUC16-
Siglec-9 binding may trigger an inhibitory response in
circulating cytotoxic immune cells even before they inter-
act with the tumor. In other words, sMUC16-Siglec-9
binding may result in inhibitory priming of the immune
cells leading to compromised anti-tumor immunity. The
occurrence of immune suppression in ovarian cancer
patients is a common observation [43-50]. sMUC16-
Siglec-9 binding is likely one of many molecular events
that contribute to attenuation of anti-tumor immune
responses. Our ongoing work is focused on determining
the cytokine release and activation capacity of immune
cells once sMUC16 binds to Siglec-9.
Competent Siglec-9pos immune cells entering the tumor
microenvironment may adhere to the cancer cells via
csMUC16. Siglecs have previously been shown to act as
adhesion receptors. MUC1, another prominent member
of the mucin family has been previously shown to be a
ligand for Siglec-1 and Siglec-4a [36,51]. MUC1-Siglec-4a
binding promotes the perineural invasion of pancreatic
cancer cells [36]. Because Siglec-9 is an inhibitory recep-
tor, the interaction between csMUC16 and Siglec-9 may
not necessarily lead to enhanced immune recognition of
Figure 6 sMUC16-Siglec-9 binding specificity. A, Siglec-7 (top panel) and Siglec-9 (bottom panel) expressing Jurkat cells were incubated for 24 h 
in media, media containing OVCAR-3 derived sMUC16 (50,000 U of CA125/ml), or in 10% media containing 90% peritoneal fluid (PF) from ovarian can-
cer patients (PT #30 and PT #42). The VK-8 antibody was used to detect binding of sMUC16 to the cells by flow cytometry. B, Siglec-9 expressing Jurkat 
cells were incubated with native and partially desialylated sMUC16 (50,000 U of CA125/ml) for 3 h. Cells were labeled with VK8 and the amount of 
sMUC16 present on the surface was determined by flow cytometry. Mean and standard deviation of three separate experiments (p < 0.05) is shown.
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Figure 7 Siglec-9 binds to csMUC16 and mediates immune cell-target cell binding. A, Siglec-9 expressing Jurkat cells were stained with Cell-
Tracker Blue and MUC16negOVC or MUC16posOVC cells were stained with CellTracker Green. The Jurkat cells and tumor targets were mixed in 1:1 ratio, 
incubated for 30 min at room temperature and conjugate formation was determined by flow cytometry as described previously [16]. Mean and stan-
dard deviation data for percent conjugation obtained from three independent flow cytometry experiments are summarized in the bar chart. B, A di-
rect 96-well plate-based cell adhesion assay was also used to measure binding of MUC16posOVC and Siglec-9 expressing Jurkat cells. Ovarian tumor 
cells were plated in 96-well plates. Calcein AM labeled Siglec-9pos or Siglec-7pos Jurkat cells were added to the wells. After 25 min incubation wells were 
washed three times and the amount of fluorescence remaining in the wells was measured. Data shown is mean of six experiments.
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the tumor but instead cause protection of the cancer
cells.
Finally, the anti-adhesive properties of csMUC16 allow
the cancer cells to evade immune recognition by the
Siglec-9neg immune cells. As shown in our other study
[19], csMUC16 prevents efficient immune synapse for-
mation between cancer cells and NK cells. Thus, the pro-
adhesive and anti-adhesive properties of csMUC16 are of
great benefit to the tumor and work in tandem to provide
immune protection during the development and progres-
sion of ovarian cancer.
The identification of Siglec-9 as the receptor for
MUC16 also has significance in the development of a
novel test to monitor ovarian cancer progression. Serum
CA125 levels are routinely monitored in patients who are
already undergoing treatment for ovarian cancer. A
decrease in serum CA125 indicates a positive response to
the treatment regimen, whereas increase in this marker
above a nadir concentration suggests recurrence of the
tumor [13,14,52]. One major factor that impairs efficient
detection of CA125 (MUC16) and other mucinous cancer
antigens in the sera is their degradation by the liver. Cir-
culating mucins are rapidly cleared by hepatic reticuloen-
dothelial cells via lectins specific for galactose/N-
acetylgalactosamine (tolerating α2,3-sialylation), man-
nose/N-acetylgalactosamine-4-sulfate, and hyaluronan
receptors and the scavenger receptors [53]. Hepatic
uptake of mucins therefore hampers efficient detection of
these tumor antigens in cancer patients. The binding of
sMUC16 to Siglec-9 on the surface of specific immune
subsets may preclude the uptake and degradation of the
mucin. Therefore, immune cell bound sMUC16 may
p r o v e  t o  b e  a  m o r e  r e l i a b l e  s o u r c e  f o r  m e a s u r i n g  t h e
changes in CA125 levels in ovarian cancer patients. We
are currently investigating the potential of monitoring
immune cell bound sMUC16 as a more sensitive diagnos-
tic assay to predict recurrence of ovarian cancer.
Conclusions
In this study we have identified Siglec-9 as the immune
cell receptor for MUC16. Our previous studies have indi-
cated that sMUC16 and csMUC16 serve an important
Figure 8 Monocytes bind to tumor cells via csMUC16-Siglec-9 interaction. Monocytes were purified from PBMC of healthy donors using the Ro-
setteSep monocyte isolation kit (Stem Cell Technologies). The monocytes were labeled with Calcein AM and added to wells containing either 
csMUC16pos-OVC or csMUC16neg-OVC. After incubation and washing, the Calcein-labeled monocytes bound to the tumor cells were measured on a 
fluorescence plate reader. To demonstrate that binding was occurring via Siglec-9, matching Calcein AM-labeled monocytes were pre-treated with 
anti-Siglec-9 blocking antibody (Clone 191240, R&D Systems) prior to conducting the cell binding assay. Data shown is mean of three independent 
measurements.
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immunomodulatory role, allowing tumor cells to escape
recognition by NK cells. Siglec-9 is an inhibitory receptor.
The demonstration that sMUC16 and csMUC16 are
ligands of Siglec-9 now allows us to further define the
molecular mechanisms leading to the attenuation of
immune responses by this mucin.
Methods
Sample Processing
The peripheral blood and peritoneal fluid samples were
obtained from nine epithelial ovarian cancer patients
(designated PT#24, PT#36, etc) recruited at the time of
their initial diagnosis. All patients and healthy donors
(designated HD#1, HD#2, etc) signed an informed con-
sent, and the studies were approved by the Institutional
Review Board of University of Wisconsin-Madison. The
peripheral blood and peritoneal fluid samples were pro-
cessed as described previously [20]. The serum CA125
levels of patients and healthy donors and other demo-
graphic information is provided as Supplementary Table
1.
Flow Cytometry
Cryopreserved or freshly obtained mononuclear cells
from the peripheral blood or peritoneal fluid samples
were analyzed. The cells were processed and labeled with
antibodies as described previously [20]. For blocking pur-
poses, cells were first incubated for 15 minutes with goat
antibody before staining with the anti-MUC16 antibody
VK8, or the anti-galectin-1 antibody, LGALS-1 (Abnova,
Taipei, Taiwan). After washing, FITC- or APC-conju-
gated goat anti-mouse (GAM) secondary antibody was
added at 1:100 or 1:150 dilutions, respectively and the
cells were incubated with mouse IgG for 15 minutes to
block any additional Fab sites on the GAM secondary.
The cells were then incubated with various cocktails of
directly conjugated antibodies to stain for CD3 (APC-
Cy7), CD45 (PerCP-Cy5.5), CD33 (PerCP-Cy5.5), CD56
(Alexa® 700), CD16 (PE-Cy7), CD19 (PE), Siglec-9 (FITC),
or Siglec-7 (PE). After a final wash, cells were resus-
pended in 300 μL of phosphate buffered saline containing
1% bovine serum albumin (PBS-BSA). Immediately
before data acquisition on an LSRII (Beckton Dickinson)
flow cytometer, the viability indicator DAPI (1:300; BD
Biosciences) was added to each sample. Each fluorophore
was compensated by automatic computerized compensa-
tion. To compare the values of samples analyzed on dif-
ferent days, SPHERO™ Rainbow Fluorescent Particles
(BD Biosciences) were used to set instrument voltages.
Data was analyzed by FlowJo software (v. 8.5.3, TreeStar)
and data plotting and statistical analysis was done using
GraphPad Prism software (v. 4, GraphPad Software, Inc.).
Western and Far-Western Blotting
The sMUC16 (isolated from culture media of OVCAR-3
cells as described earlier [10]) and the bovine glycopro-
tein, fetuin, were separated on a 4% stacking/7.5% resolv-
ing gel. The proteins were transferred to PVDF
membrane, blocked with BSA and overlaid with either
the VK-8 antibody or Siglec-9-human Fc chimera (2.5
nM) (R&D Systems). Horseradish peroxidase conjugated
goat anti-mouse or a goat anti-human Fc secondary anti-
bodies were used for detection.
For inhibition of Siglec-9 binding to sMUC16 by fetuin
or asialofetuin, the Siglec-9-human Fc was pre-incubated
for 5 min with 3-fold molar excess of fetuin or asialofe-
tuin. The Siglec-9-human-Fc along with the fetuin or
asialofetuin was overlaid on membranes blotted with
sMUC16 and binding was detected as described above.
Desialylation of MUC16
sMUC16 (2000 U of CA125) isolated from the condi-
tioned media of OVCAR-3 cells was treated with 1U of
neuraminidase from Clostridium perfringens (Sigma
Aldrich) in phosphate buffered saline (pH 7.4) in a total of
100 μL for 16 h at 37°C. Control sMUC16 samples were
treated under identical conditions except that neuramini-
dase was not added.
For desialylation experiments of immune cells, PBMC
(1-2 × 106) freshly isolated from ovarian cancer patients
were resuspended in 500 μl phosphate buffered saline
(pH 7.4). Neuraminidase (0.5 U/ml) was added and the
cells were incubated at 37°C for 15 min. For controls,
PBMC's from the same patients were incubated under
identical conditions in buffer but neuraminidase was not
added. After digestion, the test and control cells were
washed with phosphate buffered saline containing 1%
bovine serum albumin and sMUC16 bound to the cells
was determined by flow cytometry.
Binding of sMUC16 to Siglec expressing Jurkat cells
The Siglec-7pos and Siglec-9pos Jurkat cells were developed
as described in a previous report [34]. The cells were
washed in culture media (RPMI 1640 containing 10%
fetal calf serum, non-essential amino acids and G418) and
incubated for different time points in media containing
native or desialylated sMUC16 (25,000-50,000 U CA125/
ml) isolated from OVCAR-3 cells, or in a mixture of 90%
peritoneal fluid, and 10% fetal calf serum. Following incu-
bation, the cells were washed twice and stained for flow
cytometry as described above.
Cell conjugation assays
MUC16 knockdown OVCAR-3 (MUC16negOVC, previ-
ously designated as #7 cells) and the correspondingBelisle et al. Molecular Cancer 2010, 9:118
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MUC16 expressing OVCAR-3 (MUC16posOVC, previ-
ously designated as #12 cells) sublines were obtained as
reported previously [16,37]. Siglec-9 and Siglec-7-
expressing Jurkat cells were labeled with 5 μM Cell-
Tracker Blue (Invitrogen) for 25 minutes at 37°C in 5%
CO2. Concurrently, MUC16negOVC and MUC16posOVC
were harvested and dyed with 1.25 pM CellTracker Green
(Invitrogen) under identical conditions. After washing off
excess dye with PBS, cells were resuspended in PBS con-
taining 1% BSA. Siglec-9 and Siglec-7 expressing Jurkat
c e l l s  w e r e  p l a c e d  i n  f l o w  t u b e s  w i t h  e i t h e r
MUC16negOVC or MUC16posOVC cells in a 1:1 ratio and
centrifuged for 2 minutes at 100 g. Tubes were incubated
for 30 minutes at room temperature, and vortexing was
avoided. Immediately before data acquisition on an LSRII
(Beckton Dickinson) flow cytometer, the viability indica-
tor DAPI (BD Biosciences) was added to each sample.
For microtiter plate based assays, the MUC16pos-OVC,
MUC16neg-OVC and OVCAR-3 cells (1 × 105/well) were
cultured for two days in 96-well plates. On the day of the
assay, Siglec-9 and Siglec-7 expressing Jurkat cells or
monocytes isolated from the blood of healthy donors
were labeled with Calcein AM (0.1 μM) for 30 mins at
37°C. Calcein AM labeled Jurkat cells or monocytes (1 ×
105/well) were added to wells containing the ovarian
tumor targets. Monocytes were freshly isolated using the
RosetteSep monocyte isolation kits (Stem Cell Technolo-
gies). Tissue culture plates were incubated for 25 min at
37°C in a 5% CO2 environment. After incubation, wells
were washed 4-6 times with PBS containing 1% BSA. The
plates were analyzed on a fluorescent plate reader to
determine the binding of Siglec-9 and Siglec-7 expressing
Jurkat cells to the ovarian tumor targets.
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